Edesa Biotech Announces Chief Financial Officer Transition
Edesa Biotech (NASDAQ:EDSA) has announced a leadership transition in its financial department. Peter J. Weiler will assume the role of Chief Financial Officer effective May 1, 2025, replacing Stephen Lemieux who is stepping down to pursue other opportunities.
Weiler brings significant experience from the biotech and pharmaceutical sectors, most recently serving as President of Exzell Pharma. His prior roles include VP of Business Development at Biosyent Inc. and various positions at Cipher Pharmaceuticals. He holds an MBA from Ivey School of Business, an MSc in Biology, and a BSc in Biology with a Diploma in Accounting.
Following the transition, Lemieux will continue providing financial advisory services to Edesa. CEO Par Nijhawan expressed confidence in Weiler's ability to support the company's pipeline advancement and strategic initiatives.
Edesa Biotech (NASDAQ:EDSA) ha annunciato un cambiamento nella leadership del suo dipartimento finanziario. Peter J. Weiler assumerà il ruolo di Chief Financial Officer a partire dal 1° maggio 2025, sostituendo Stephen Lemieux che si dimette per perseguire altre opportunità.
Weiler porta con sé una significativa esperienza nei settori biotech e farmaceutico, avendo recentemente ricoperto il ruolo di Presidente di Exzell Pharma. Le sue esperienze precedenti includono VP dello Sviluppo Commerciale presso Biosyent Inc. e diverse posizioni presso Cipher Pharmaceuticals. Ha conseguito un MBA presso la Ivey School of Business, un MSc in Biologia e una BSc in Biologia con un Diploma in Contabilità.
Dopo la transizione, Lemieux continuerà a fornire servizi di consulenza finanziaria a Edesa. Il CEO Par Nijhawan ha espresso fiducia nella capacità di Weiler di supportare l'avanzamento del portafoglio dell'azienda e le iniziative strategiche.
Edesa Biotech (NASDAQ:EDSA) ha anunciado una transición en el liderazgo de su departamento financiero. Peter J. Weiler asumirá el cargo de Chief Financial Officer a partir del 1 de mayo de 2025, reemplazando a Stephen Lemieux, quien dejará el puesto para buscar otras oportunidades.
Weiler aporta una experiencia significativa de los sectores biotech y farmacéutico, habiendo sido recientemente Presidente de Exzell Pharma. Sus roles anteriores incluyen VP de Desarrollo Comercial en Biosyent Inc. y diversas posiciones en Cipher Pharmaceuticals. Tiene un MBA de la Ivey School of Business, un MSc en Biología y una BSc en Biología con un Diploma en Contabilidad.
Tras la transición, Lemieux continuará brindando servicios de asesoría financiera a Edesa. El CEO Par Nijhawan expresó confianza en la capacidad de Weiler para apoyar el avance del pipeline de la empresa y las iniciativas estratégicas.
Edesa Biotech (NASDAQ:EDSA)는 재무 부서의 리더십 전환을 발표했습니다. Peter J. Weiler는 2025년 5월 1일부터 Chief Financial Officer 역할을 맡으며, Stephen Lemieux는 다른 기회를 추구하기 위해 사임합니다.
Weiler는 최근 Exzell Pharma의 사장으로 재직하며 생명공학 및 제약 분야에서 상당한 경험을 쌓았습니다. 이전에는 Biosyent Inc.의 사업 개발 부사장과 Cipher Pharmaceuticals의 여러 직책을 역임했습니다. 그는 Ivey School of Business에서 MBA를, 생물학에서 MSc를, 생물학과 회계학에서 BSc와 회계학 디플로마를 취득했습니다.
전환 후, Lemieux는 Edesa에 재무 자문 서비스를 계속 제공할 것입니다. CEO Par Nijhawan은 Weiler가 회사의 파이프라인 발전과 전략적 이니셔티브를 지원할 수 있는 능력에 대한 신뢰를 표명했습니다.
Edesa Biotech (NASDAQ:EDSA) a annoncé une transition de leadership dans son département financier. Peter J. Weiler assumera le rôle de Chief Financial Officer à compter du 1er mai 2025, remplaçant Stephen Lemieux qui se retire pour poursuivre d'autres opportunités.
Weiler apporte une expérience significative des secteurs de la biotechnologie et de la pharmacie, ayant récemment été président d'Exzell Pharma. Ses précédents postes incluent VP du développement commercial chez Biosyent Inc. et divers postes chez Cipher Pharmaceuticals. Il détient un MBA de l'Ivey School of Business, un MSc en biologie et un BSc en biologie avec un diplôme en comptabilité.
Suite à cette transition, Lemieux continuera à fournir des services de conseil financier à Edesa. Le CEO Par Nijhawan a exprimé sa confiance dans la capacité de Weiler à soutenir l'avancement du portefeuille de l'entreprise et les initiatives stratégiques.
Edesa Biotech (NASDAQ:EDSA) hat einen Führungswechsel in seiner Finanzabteilung bekannt gegeben. Peter J. Weiler wird ab dem 1. Mai 2025 die Rolle des Chief Financial Officer übernehmen und Stephen Lemieux ersetzen, der zurücktritt, um andere Möglichkeiten zu verfolgen.
Weiler bringt umfassende Erfahrung aus den Bereichen Biotechnologie und Pharmazie mit, zuletzt als Präsident von Exzell Pharma tätig. Zuvor war er VP für Geschäftsentwicklung bei Biosyent Inc. und hatte verschiedene Positionen bei Cipher Pharmaceuticals inne. Er hat einen MBA von der Ivey School of Business, einen MSc in Biologie und einen BSc in Biologie mit einem Diplom in Buchhaltung.
Nach dem Wechsel wird Lemieux weiterhin finanzielle Beratungsdienste für Edesa anbieten. CEO Par Nijhawan äußerte Vertrauen in Weilers Fähigkeit, die Fortschritte des Unternehmensportfolios und strategische Initiativen zu unterstützen.
- New CFO brings extensive pharmaceutical industry experience and strategic expertise
- Current CFO will continue providing advisory services ensuring smooth transition
- None.
TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the appointment of Peter J. Weiler as Chief Financial Officer, effective May 1, 2025. Mr. Weiler will succeed Stephen Lemieux, who will be stepping down from the role effective May 1, 2025, to pursue other professional opportunities.
Mr. Weiler brings extensive experience in finance and corporate strategy within the biotechnology and pharmaceutical industries. Since August 2018, Mr. Weiler served as President of Exzell Pharma, Inc., a privately held, commercial-stage pharmaceutical company. From August 2017 to August 2018, Mr. Weiler served as Vice President of Business Development at Biosyent Inc. Prior to that, he served in various roles at Cipher Pharmaceuticals Inc., including Vice President of Business Development from January 2015 to June 2017, Senior Director from January 2012 to January 2014, and Director from December 2008 to December 2011. Prior to Cipher, he served as Senior Director of Investment Analysis at DRI Capital Inc. and held research and financial positions at Eli Lilly Canada Inc. Mr. Weiler holds a Master of Business Administration degree from the Ivey School of Business, University of Western Ontario, a Masters of Science in Biology from the University of Western Ontario, and a Bachelor of Science (Honors Biology) degree and Diploma in Accounting from Wilfrid Laurier University.
“We are thrilled to welcome Peter to Edesa at this pivotal time in our development,” said Par Nijhawan, MD, Chief Executive Officer of Edesa Biotech. “I have worked closely with Peter in the past in connection with other business opportunities, and he brings a wealth of managerial expertise that I believe will be invaluable as we continue to advance our pipeline and seek strategic opportunities for our drug candidates.”
Following the planned transition, Mr. Lemieux will continue to provide financial advisory services to Edesa. “On behalf of Edesa and our Board of Directors, we thank Stephen for his financial leadership and contributions to the company, and we wish him well in his new career roles,” said Dr. Nijhawan.
About Edesa Biotech, Inc.
Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Its clinical pipeline is focused on two therapeutic areas: Medical Dermatology and Respiratory. In Medical Dermatology, Edesa is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (
Edesa Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.
Contact:
Gary Koppenjan
Edesa Biotech, Inc.
investors@edesabiotech.com
